Diabetes

Adherence to Mediterranean diet-based interventions was associated with reductions in BP, triglycerides, total cholesterol, and LDL-C, as well as increases in HDL-C among children and adolescents.

Results from secondary analysis suggest future work is needed to extend the prevention intervention to address additional chronic conditions and substance use.

The antigen-specific immunotherapy preserves endogenous insulin production via intralymphatic injection of recombinant GAD65 protein, according to Diamyd Medical.

The expert panel concludes by analyzing a patient case and offering final insights on customizing treatment for complex geriatric diabetes patients, taking into account cardiovascular health, weight management, and renal function considerations.

Key opinion leaders explore methods for optimizing treatment in older adults with type 2 diabetes, focusing on streamlining regimens and the process of deprescribing, with particular emphasis on defining and implementing the deprescribing approach.

Experts examine strategies for managing treatment modifications in older adults with type 2 diabetes, weighing the approaches, challenges, and advantages of combination therapy regimens.

Leading experts in geriatric diabetes care explore comprehensive aspects of insulin therapy, including dosing strategies, available injectable options, and methods for tailoring glucose control in elderly patients.

The panelists analyze a patient case, examining treatment profiles, adherence factors, and drug class selection criteria while discussing strategies to enhance elderly care.

Key opinion leaders explore strategies for enhancing elderly patient care by implementing American Diabetes Association guidelines on glycemic targets and long-term management in geriatric settings.

In the mouse model of type 1 diabetes, a combined harmine/exendin-4 therapy resulted in an up to 7-fold increase in β cell numbers over 3 months, reported investigators.

Long-term risk of death decreased by 26% and risk for vascular complications decreased by 40% in persons who remained diabetes-free for 4 years, according to new data.

The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.

The international statement targets primary care clinicians and endocrinologists with detailed guidance on monitoring disease progression and providing education.

Key opinion leaders in the management of diabetes delineate the definition of older patients and examine the implications of homeostenosis, a condition that disrupts homeostatic mechanisms in aging individuals.

Medha Munshi, MD, and Javier Morales, MD, FACP, FACE, emphasize the significance of personalized diabetes management, emphasizing age and other patient-specific factors as crucial considerations for optimizing care.

ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.

Your daily dose of the clinical news you may have missed.

ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.

Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Global prevalence of adults 65 years and older with T1D increased 180% in the past 30 years, researchers reported.

The panel of experts from UCSD concludes the discussion on delaying the onset of stage 3 T1D by providing key takeaways and clinical advice on the treatment of patients with this condition.

Focusing on the utilization of teplizumab, the expert panel from UCSD shares insights in how to select patients for this treatment and provide practical tips for the infusion process, and infusion location options.

The panel reviews the TN-10 trial investigating teplizumab, focusing on patient inclusion criteria, patient outcomes, and adverse reactions.

Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.

Schafer Boeder, MD and Andrea Stallings, PA delve into the intricacies of autoantibody screening tests for T1D with detailed insights on their methodologies, interpretation nuances, and practical analysis considerations.

Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.

Addressing the significance of acting early in T1D care, a group of diabetes experts delve into the impact of delaying intervention during stage 2 of the condition.

Schafer Boeder, MD and his colleagues provide a comprehensive overview of the stages of T1D in patients with diabetes, highlighting the various signs and symptoms associated with each stage.

A panel of experts on diabetes management introduce themselves and provide an overview of the condition, highlighting risk factors, disease burden, and the benefits of collaborative care.